CRVONasdaq

CervoMed Inc.

Healthcare·Neurology·Phase 2·Boston, MA, United States
Neurology

CervoMed Inc. (CRVO): 1 pipeline candidate · ~5 mo cash runway. Updated within the last hour.

5.0/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway1.4

5.0 months

Financial Health9.4

D/E 0.42 · 0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for CervoMed Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$23.0M

Cash

$7.9M

Quarterly Burn

$8.0M

Runway

5.0 mo

Revenue

$0

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2026
Today~7 mo out
Catalyst within runway

Pipeline (1 candidate)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

36

Total value held

$8.2M

HolderSharesValue
morgan stanley739,892$2.9M
vanguard capital management llc632,404$2.5M
millennium management llc208,908$823K
geode capital management, llc74,371$293K
renaissance technologies llc63,904$252K
blackrock, inc.51,660$204K
xtx topco ltd38,487$152K
citizens financial group inc/ri37,477$148K
vanguard fiduciary trust co36,151$142K
northern trust corp30,044$118K

Showing top 10 of 36 institutional holders of CervoMed Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·1 FDA decision·CEO: Dr. John J. Alam M.D.

Frequently asked questions

How many drug candidates are in CervoMed Inc.'s pipeline?

CervoMed Inc. (CRVO) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is CervoMed Inc.'s lead drug candidate?

CervoMed Inc.'s most advanced tracked candidate is neflamapimod (Phase 2) for dementia with Lewy bodies (DLB).

What is CervoMed Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, CervoMed Inc. has approximately 5.0 months of cash runway.

What is CervoMed Inc.'s market capitalization?

CervoMed Inc.'s market capitalization is approximately $23.0M.

Who is the CEO of CervoMed Inc.?

Dr. John J. Alam M.D. is the chief executive officer of CervoMed Inc. (CRVO).

Get the full picture on CervoMed Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.